Gladius Capital Management LP Purchases 1,742 Shares of Zynex, Inc. (NASDAQ:ZYXI)

Gladius Capital Management LP grew its holdings in Zynex, Inc. (NASDAQ:ZYXI) by 53.4% in the third quarter, HoldingsChannel reports. The fund owned 5,002 shares of the company’s stock after buying an additional 1,742 shares during the period. Gladius Capital Management LP’s holdings in Zynex were worth $41,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Royce & Associates LP raised its stake in Zynex by 9.2% in the third quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock valued at $2,099,000 after purchasing an additional 21,781 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in shares of Zynex by 72.7% during the 3rd quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock worth $652,000 after acquiring an additional 33,649 shares during the period. Janney Montgomery Scott LLC increased its holdings in shares of Zynex by 22.3% during the third quarter. Janney Montgomery Scott LLC now owns 144,439 shares of the company’s stock worth $1,179,000 after buying an additional 26,368 shares in the last quarter. Investment Partners Asset Management Inc. acquired a new stake in shares of Zynex during the 3rd quarter valued at $96,000. Finally, Cim LLC boosted its holdings in shares of Zynex by 6.1% during the 2nd quarter. Cim LLC now owns 43,581 shares of the company’s stock valued at $406,000 after acquiring an additional 2,508 shares in the last quarter. Institutional investors own 29.68% of the company’s stock.

Analyst Ratings Changes

ZYXI has been the subject of several recent research reports. Royal Bank of Canada lowered their price objective on Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. HC Wainwright upped their price target on shares of Zynex from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, October 25th.

Zynex Stock Down 3.6 %

Shares of ZYXI opened at $7.80 on Friday. The stock’s 50-day moving average price is $8.23 and its two-hundred day moving average price is $8.87. Zynex, Inc. has a 12 month low of $7.15 and a 12 month high of $13.77. The company has a market capitalization of $248.43 million, a PE ratio of 52.00 and a beta of 0.53. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66.

Zynex (NASDAQ:ZYXI) last posted its quarterly earnings data on Thursday, October 24th. The company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.01. Zynex had a return on equity of 13.05% and a net margin of 2.49%. The company had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. During the same period in the previous year, the firm earned $0.10 earnings per share. The firm’s quarterly revenue was up .1% on a year-over-year basis. On average, analysts anticipate that Zynex, Inc. will post 0.2 EPS for the current year.

Insider Transactions at Zynex

In other Zynex news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $8.59, for a total transaction of $85,900.00. Following the completion of the sale, the chief financial officer now directly owns 44,878 shares in the company, valued at approximately $385,502.02. This trade represents a 18.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 24,000 shares of company stock worth $208,440. Company insiders own 52.13% of the company’s stock.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.